Our MISSION AT Foster Rosenblatt
Foster Rosenblatt is an international advisory firm exclusively focused on life sciences. Our clients recognize us as a premier service provider in predictive analytics, forecasting, commercial analytics and pricing & market access. We are deep content experts supporting industry manufacturers, the financial community & law firms.
Our expertise in the commercial, clinical & basic sciences allows us to credibly work across the pharma/biotech, medtech, diagnostic and animal health sectors. We work in all therapeutic areas & support all product/market lifecycle stages. Additionally, we have a standalone Oncology Center of Excellence.
We also provide an array of professional and organizational development services. We offer organizational diagnostics, learning frameworks, and marketing science training courses. Our in-house & public seminars have been the gold standard in industry for the past 25 years.
News & Events
- Strategic Answers Inc. (SAI) Has Been Acquired By Foster Rosenblatt. SAI Is A Leading Provider Of ONCOLOGY Patient Data, Analytics And Consulting. This Acquisition Significantly Increases Our Ability To Address The Increasingly Complex Needs Of Our Oncology Clients. SAI Is Now Known As F|R Oncology. The Group Focuses On Oncology Stakeholder Research, Future Forecast Scenarios, Pricing & Market Access, Commercial Analytics & ROI, Competitive Intelligence, Brand Planning, Business Development Support, And Insightful Meeting Analysis.
- The F|R OncoEdge Patient Prevalence Tool Is Now Fully Integrated Into Our Oncology Analytics And Consulting Work. This Tool Identifies Highly Relevant Current & Future Treatable Patient Populations. The Tool Provides Real-World Proprietary Treatment Algorithms Validated By KOLs/Community MDs That Outline Percent Of Patients Diagnosed By Stage And/Or Histologic Subtypes, Treatment Options Received & Recurrence Rates/Patterns/Timelines. This Model Determines Patient Incidence & Prevalence Using A Retrospective Regression Approach That Isolates Treatable Patient Populations As Well As Palliated Patients.